Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Facility significantly increases future financial and operational flexibilityUp to $200M available, with$30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half 2026Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the ...